The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals

Journal of Immunology

Volumn 182, Issue 5, 2009, Pages 3318-3326

  Crompton, Peter D ^a   Mircetic, Marko ^a   Weiss, Greta ^a   Baughman, Amy ^a   Huang, Chiung Yu ^a   Topham, David J ^b   Treanor, John J ^b   Sanz, Iñaki ^b   Lee, F Eun Hyung ^b   Durbin, Anna P ^c   Miura, Kazutoyo ^a   Narum, David L ^a   Ellis, Ruth D ^a   Malkin, Elissa ^a,d   Mullen, Gregory E D ^a   Miller, Louis H ^a   Martin, Laura B ^a   Pierce, Susan K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; APICAL MEMBRANE AG 1; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN; UNCLASSIFIED DRUG; ALUMINUM HYDROXIDE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; EPITOPE; IMMUNOLOGICAL ADJUVANT; LIGAND; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; INNATE IMMUNITY; MALARIA; MEMORY CELL; PLASMA CELL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROPHYLAXIS; ANIMAL; B LYMPHOCYTE; CELL CULTURE; CPG ISLAND; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; PHASE 1 CLINICAL TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANIMALS; B-LYMPHOCYTE SUBSETS; CELLS, CULTURED; CLINICAL TRIALS, PHASE I AS TOPIC; CPG ISLANDS; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LIGANDS; MALARIA; MALARIA VACCINES; OLIGODEOXYRIBONUCLEOTIDES; PLASMODIUM FALCIPARUM; TOLL-LIKE RECEPTOR 9;

EID: 64849115291     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803596     Document Type: Article

References (33)

1. Plotkin, S. A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47: 401-409.
2. Crotty, S., and R. Ahmed. 2004. Immunological memory in humans. Semin. Immunol. 16: 197-203.
3. Lanzavecchia, A., N. Bernasconi, E. Traggiai, C. R. Ruprecht, D. Corti, and F. Sallusto. 2006. Understanding and making use of human memory B cells. Immunol. Rev. 211: 303-309.
4. Langhorne, J., F. M. Ndungu, A. M. Sponaas, and K. Marsh. 2008. Immunity to malaria: more questions than answers. Nat. Immunol. 9: 725-732.
5. Cagigi, A., A. Nilsson, A. De Milito, and F. Chiodi. 2008. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 26: 3016-3025.
6. Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171: 4969-4973.
7. Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9: 1131-1137.
8. el-Ad, B., Y. Roth, A. Winder, Z. Tochner, T. Lublin-Tennenbaum, E. Katz, and T. Schwartz. 1990. The persistence of neutralizing antibodies after revaccination against smallpox. J. Infect. Dis. 161: 446-448.
9. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357: 1903-1915.
10. Mamani-Matsuda, M., A. Cosma, S. Weller, A. Faili, C. Staib, L. Garcon, O. Hermine, O. Beyne-Rauzy, C. Fieschi, J. O. Pers, et al. 2008. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 111: 4653-4659.
11. Nanan, R., D. Heinrich, M. Frosch, and H. W. Kreth. 2002. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory Blymphocytes. Vaccine 20: 498-504.
12. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
13. Chiron, D., I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego. 2008. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205-2213.
14. Quinn, C. P., P. M. Dull, V. Semenova, H. Li, S. Crotty, T. H. Taylor, E. Steward-Clark, K. L. Stamey, D. S. Schmidt, K. W. Stinson, et al. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis. 190: 1228-1236.
15. Blanchard Rohner, G., M. D. Snape, D. F. Kelly, T. John, A. Morant, L. M. Yu, A. Borkowski, F. Ceddia, R. Borrow, C. A. Siegrist, and A. J. Pollard. 2008. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J. Immunol. 180: 2165-2173.
16. Leyendeckers, H., M. Odendahl, A. Lohndorf, J. Irsch, M. Spangfort, S. Miltenyi, N. Hunzelmann, M. Assenmacher, A. Radbruch, and J. Schmitz. 1999. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur. J. Immunol. 29: 1406-1417.
17. van der Kolk, L. E., J. W. Baars, M. H. Prins, and M. H. van Oers. 2002. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100: 2257-2259.
18. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
19. Davis, T. A., A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy. 2000. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18: 3135-3143.
20. Cambridge, G., M. J. Leandro, J. C. Edwards, M. R. Ehrenstein, M. Salden, M. Bodman-Smith, and A. D. Webster. 2003. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48: 2146-2154.
21. Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484.
22. Halperin, S. A., G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden. 2003. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21: 2461-2467.
23. Halperin, S. A., S. Dobson, S. McNeil, J. M. Langley, B. Smith, R. McCall-Sani, D. Levitt, G. V. Nest, D. Gennevois, and J. J. Eiden. 2006. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24: 20-26.
24. Mullen, G. E., R. D. Ellis, K. Miura, E. Malkin, C. Nolan, M. Hay, M. P. Fay, A. Saul, D. Zhu, K. Rausch, et al. 2008. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3: e2940.
25. Crotty, S., R. D. Aubert, J. Glidewell, and R. Ahmed. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286: 111-122.
26. Liang, K. Y., and S. L. Zeger. 1986. Longitudinal data analysis using generalized linear models. Biometrika 73: 13-22.
27. Wrammert, J., K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N. Y. Zheng, I. Mays, L. Garman, C. Helms, J. James, G. M. Air, J. D. Capra, R. Ahmed, and P. C. Wilson. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
28. Sasaki, S., X. S. He, T. H. Holmes, C. L. Dekker, G. W. Kemble, A. M. Arvin, and H. B. Greenberg. 2008. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 3: e2975.
29. Bernasconi, N. L., N. Onai, and A. Lanzavecchia. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504.
30. Hand, T. W., and S. M. Kaech. 2008. Intrinsic and extrinsic control of effector T cell survival and memory T cell development. Immunol. Res. In press.
31. Odendahl, M., H. Mei, B. F. Hoyer, A. M. Jacobi, A. Hansen, G. Muehlinghaus, C. Berek, F. Hiepe, R. Manz, A. Radbruch, and T. Dorner. 2005. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105: 1614-1621.
32. Eisenbarth, S. C., O. R. Colegio, W. O'Connor, F. S. Sutterwala, and R. A. Flavell. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122-1126.
33. Crompton, P. D., B. Traore, K. Kayentao, S. Doumbo, A. Ongoiba, S. A. Diakite, M. A. Krause, D. Doumtabe, Y. Kone, G. Weiss, et al. 2008. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J. Infect. Dis. 198: 1265-1275.